TARGET Study: Not Quite A Bull’s-Eye For COX-2 Inhibitors Over NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
Novartis' TARGET study found that the COX-2 inhibitor lumiracoxib has approximately one-third the rate of gastrointestinal side effects compared to prescription doses of non-steroidal anti-inflammatory drugs